BSE: NOVARTIND CMP: Rs 1440.95 P/E: 38.09x ROCE: 16.25% 6M Ret: +84.85% Div Yld: 1.74% ATH: Rs 1589.20
Key Performance Indicators
Novartis India trades at Rs 1440.95 on BSE (NOVARTIND), with a market capitalisation of Rs 3548.91 crore. The price-to-earnings ratio is 38.09x. Return on capital employed stands at 16.25%. The six-month return is +84.85%. Quarterly net profit is Rs 25.25 crore (-13.82% year-on-year change). Quarterly sales stand at Rs 90.55 crore (+7.95% year-on-year). The dividend yield is 1.74%. The all-time high is Rs 1589.20, 10.3% above the current price.
Highlights
Novartis India has delivered a six-month return of 84.85%, with a market capitalisation of Rs 3548.91 crore at the current price of Rs 1440.95. The all-time high of Rs 1589.20 sits 10.3% above the current price, indicating the stock has corrected from its historical peak and offers headroom for appreciation toward that level. The company's ROCE of 16.25% — above the 15% quality threshold, indicating the business generates meaningful returns above the cost of capital — is a key distinguishing fundamental metric.
The P/E of 38.09x is at or below the Indian market average — an attractive entry multiple if the ROCE and earnings growth profile is sustainable. The dividend yield of 1.74% provides a meaningful income component — a signal of cash generation capability and management's willingness to return capital. The healthcare sector tailwinds — rising health insurance penetration, growing chronic disease burden, and government healthcare investment — provide structural support for sustained revenue and earnings growth.
Business Overview
Novartis India Limited is a subsidiary of Novartis AG — the Swiss multinational pharmaceutical giant — marketing branded prescription pharmaceutical products across cardiovascular, oncology, immunology, and specialty medicine categories in India. As a subsidiary of one of the world's largest pharmaceutical companies, Novartis India benefits from the parent's global R&D pipeline, regulatory expertise, and brand credibility with the Indian medical community. The company operates through a medical representative field force calling on specialist physicians, hospitals, and institutional healthcare buyers.
The quarterly profit of Rs 25.25 crore declining 13.82% on revenue of Rs 90.55 crore growing 7.95% year-on-year reflects a profitable branded pharmaceutical business with near-term margin pressure. The P/E of 38.09 times, dividend yield of 1.74% — the highest in this batch — and ROCE of 16.25% together describe a quality MNC subsidiary with strong income characteristics. The six-month return of 84.85% and the all-time high of Rs 1,589.20 — Rs 148.25 above the current price of Rs 1,440.95 — indicate headroom toward the historical peak.
Financial Analysis
Novartis India's most recent quarterly financial results show revenue of Rs 90.55 crore (+7.95% year-on-year) and net profit of Rs 25.25 crore (-13.82% year-on-year variation). Revenue and profit growth are broadly aligned, indicating a business that is scaling without dramatic margin compression or expansion — a stable, predictable compounding profile.
The ROCE of 16.25% is the primary quality indicator for this business. At 16.25%, the business crosses the threshold that Warren Buffett famously cited as a hallmark of exceptional businesses — generating returns on capital substantially above typical cost of capital levels, creating economic value with each rupee reinvested.
At Rs 3548.91 crore — a small-cap company — Novartis India may have limited institutional research coverage, making self-directed analysis of BSE exchange filings, quarterly results, and annual reports especially important for investors forming an investment view.
Investor Highlights
The investment case for Novartis India rests on the combination of a 16.25% ROCE — indicating a capital-efficient business with sustainable competitive advantages — and a demonstrated revenue and earnings growth trajectory that supports the current P/E of 38.09x. The combination of solid ROCE with consistent earnings growth creates a compounding engine where both business scale and per-share earnings grow simultaneously, supporting share price appreciation over a full investment cycle.
With the current price 10.3% below the all-time high of Rs 1589.20, there is established headroom toward the historical peak. If fundamental performance continues to deliver quarterly profit growth and improving ROCE, the stock has a reference target for re-rating toward the all-time high level.
The dividend yield of 1.74% provides a foundational income return that is independent of capital appreciation — a meaningful characteristic for investors who value income alongside growth. A dividend-paying company with a positive ROCE above 15% is distributing cash it does not need for reinvestment at attractive rates, implying the business generates more cash than its optimal reinvestment requirements. Investors should access the company's latest annual report and quarterly results on the BSE/NSE portal for current financial data and management commentary on the growth outlook.
Frequently Asked Questions
Q: What does Novartis India do and why has it delivered a 84.85% six-month return?
A: Novartis India operates in India's healthcare sector. The 84.85% six-month return reflects a combination of sector-level tailwinds, improving quarterly financial performance — quarterly profit changing -13.82% and revenue growing 7.95% year-on-year — and market re-rating of the company's growth and quality profile. Specific business details and catalysts are documented in BSE/NSE exchange filings.
Q: What does the ROCE of 16.25% indicate about Novartis India's business quality?
A: Novartis India's ROCE of 16.25% measures pre-tax profit generated per rupee of total capital employed. At 16.25%, the business consistently generates returns above the typical cost of capital for Indian companies — a hallmark of businesses with durable competitive advantages, whether from technology, relationships, scale, or regulatory positioning. Tracking ROCE over multiple quarters provides a leading indicator of business quality improvement or deterioration.
Q: How does the P/E of 38.09x compare to fundamentals for Novartis India?
A: The P/E of 38.09x should be assessed in conjunction with the earnings growth rate and ROCE. At 38.09x — below or at the Indian market average — the stock is conservatively priced for a business generating 16.25% ROCE, potentially representing a value opportunity if the earnings growth profile is sustained.
Q: What is Novartis India's all-time high and how far is the current price from it?
A: Novartis India's all-time high is Rs 1589.20. The current price of Rs 1440.95 is 10.3% below the all-time high, offering potential headroom for appreciation if fundamental performance supports continued market re-rating. The all-time high provides a reference ceiling that informs sentiment and potential price target discussion, though fundamental value — determined by earnings, ROCE, and growth — is the primary determinant of sustainable price levels.
Q: Where can investors access Novartis India's official financial data and disclosures?
A: Novartis India's quarterly results, annual reports, investor presentations, shareholding patterns, and all material corporate announcements are filed with BSE and are freely accessible through the exchange filing portals at nseindia.com and bseindia.com. SEBI listing regulations mandate timely disclosure of all financial results and material developments. These filings are the primary source of verified financial and operational data for investment analysis.